Printer Friendly

Aastrom receives patent expanding coverage for its single-pass perfusion technology.

Aastrom Biosciences, Inc. (Ann Arbor, MI) received United States Patent 6,835,566 from the United States Patent and Trademark Office. The patent provides expanded coverage for the company's single-pass perfusion technology to cover enhancing the biological functionality of human dendritic cells produced in cell culture. Dendritic cells are in clinical trials and experimental evaluations as vaccines for numerous forms of cancer and infectious diseases at various academic institutions and companies.

Aastrom is currently engaged in on-going clinical trial collaborations at Stanford University evaluating dendritic cells produced with this technology.

"This patent further expands Aastrom's coverage of our single-pass perfusion technology for growing human cells from bone marrow stem cells, to now include dendritic cells," said R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer of Aastrom. "Our industry-unique technology continues to support Aastrom's position as a leader in the production of novel cell- based therapeutics."

Aastrom Biosciences is a regenerative medicine company developing treatments for the repair of damaged human tissues and other medical disorders, or the generation of normal human tissues, utilizing the company's proprietary adult stem cell-based products. Aastrom's strategic position in the tissue regeneration and cell therapy sectors is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the AastromReplicell System, an industry-unique automated cell production platform used to produce cells for clinical use. Together TRCs and the AastromReplicell System provide a foundation that the company is leveraging to produce multiple Prescription Cell Products (PCPs), several of which are now in the clinical stage in the United States and EU. TRCs are the core component of the PCPs Aastrom is developing for bone grafting, peripheral vascular disease, jaw bone reconstruction and spine fusion markets. The company has also developed the AastromReplicell System for dendritic cell production for researchers and institutions developing vaccines to treat cancer and infectious diseases, under its Cell Production Products line.

Aastrom Biosciences, Inc.

+1-212-245-4577

www.aastrom.com
COPYRIGHT 2005 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Jan 1, 2005
Words:325
Previous Article:Agilix details versatility of multiplexed protein labeling technology for biomarker discovery.
Next Article:Lexicon discovers potential new therapies for cancer and bleeding disorders.
Topics:


Related Articles
Aastrom Biosciences launches AastromReplicell in Europe for use in stem cell therapy.
Aastrom Biosciences patents cassette approach to growing human cells.
Aastrom receives patent covering integrated system for producing human cells.
PIXELWORKS CHOOSES AVANT!'S JUPITERXT/SINGLEPASS-SOC.
Aastrom Biosciences receives culture device European patent.
Aastrom Biosciences receives NIH grant to expand development of cell-base approaches for bone regeneration.
AASTROM BIOSCIENCES REPORTS POSITIVE HUMAN JAW BONE RESULTS.
Nuclear cardiology; the basics; how to set up and maintain a laboratory. (CD-ROM included).

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |